2023년 FDA 승인 펩타이드 의약품

• 영문명: FDA Approved Peptide Drugs in 2023
• 발행기관: 대한약학회
• 저자명: 정혜웅(Hye Ung Jeong) 오창민(Changmin Oh) 진효언(Hyo-Eon Jin) 정종화(Jong-Wha Jung)
• 간행물 정보: 『약학회지』제68권 제2호(2024년), 79~83쪽, 전체 5쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2024.03.30

영문 초록

Peptide drugs generally show high performance in terms of safety, target affinity, and efficacy, but have limitations such as low bioavailability and short half-life. To improve this, new synthetic and analytical techniques have been developed, and the global market for peptide drugs has made great strides in the past few years, with novel peptide drugs being applied to multiple therapeutic areas. In line with this trend, 5 out of 55 new molecular entities (NMEs) approved by the FDA in the year 2023 were peptide drugs, which is an increasing trend in the last few years. In this review article, we will discuss the mechanisms of action and clinical indications, chemical structure and design, and pharmacokinetic perspectives of 6 FDA-approved peptide drugs in 2023 including 5 NMEs.

목차

서 론(Introduction)

본 론(Body)

결 론(Conclusion)

감사의 말씀(Acknowledgment)

Conflict of Interest

References

키워드

Peptide drug Trofinetide Motixafortide Rezafungin Flotufolastat F 18 Nirmatrelvir Tirzepatide